Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Yinfang Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6578-5473; OpenAlex author ID A5042554822. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Letter to the editor: "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline r… Co-author DOI 10.1016/j.surg.2024.108963↗
  2. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway. Co-author PMID 34162560↗
  3. ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer. Co-author DOI 10.18632/oncotarget.21095↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qi Zhao · 1 shared paper, 2025 · strength 0.54
  2. Zhongwei Zhang · 1 shared paper, 2021 · strength 0.19
  3. Shibing Wang · 1 shared paper, 2017 · strength 0.09
  4. Xiaodong Sun · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.